Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3410497 | 0.92 | HCRTR1 (0.36) | HCRTR1HCRTR2ACHEFKBP1AMEN1 | |
| SCHEMBL3409736 | 0.87 | HCRTR1 (0.36) | HCRTR1HCRTR2ACHE | |
| SCHEMBL3406849 | 0.87 | OPRM1 (0.39) | HCRTR1HCRTR2ACHE | |
| SCHEMBL3408728 | 0.86 | BDKRB1 (0.40) | HCRTR1HCRTR2FKBP1ALMNA | |
| SCHEMBL3410534 | 0.86 | HCRTR1 (0.37) | HCRTR1HCRTR2ACHE | |
| SCHEMBL3407386 | 0.85 | HCRTR1 (0.36) | HCRTR1HCRTR2FKBP1A | |
| SCHEMBL3413003 | 0.83 | HCRTR1 (0.36) | HCRTR1HCRTR2FKBP1AMEN1KMT2A | |
| SCHEMBL3406135 | 0.82 | HCRTR1 (0.36) | HCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL3405479 | 0.81 | HCRTR1 (0.37) | HCRTR1HCRTR2FKBP1A | |
| SCHEMBL3409667 | 0.79 | HCRTR1 (0.38) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257527-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-08 | — | — | EP | claimed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | claimed |
| WO-2009115257-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-24 | — | — | WO | claimed |
| EP-2257527-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-08 | — | — | EP | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| WO-2009115257-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | HCRTR1 4142/4885HCRTR2 3980/4885ACHE 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.